Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more
Handok (002390) - Net Assets
Latest net assets as of September 2025: ₩267.88 Billion KRW
Based on the latest financial reports, Handok (002390) has net assets worth ₩267.88 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩804.42 Billion) and total liabilities (₩536.54 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩267.88 Billion |
| % of Total Assets | 33.3% |
| Annual Growth Rate | 0.29% |
| 5-Year Change | -24.3% |
| 10-Year Change | -4.82% |
| Growth Volatility | 7.24 |
Handok - Net Assets Trend (2011–2024)
This chart illustrates how Handok's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Handok (2011–2024)
The table below shows the annual net assets of Handok from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩289.06 Billion | -15.14% |
| 2023-12-31 | ₩340.63 Billion | -10.80% |
| 2022-12-31 | ₩381.86 Billion | -0.56% |
| 2021-12-31 | ₩384.00 Billion | +0.56% |
| 2020-12-31 | ₩381.85 Billion | +11.00% |
| 2019-12-31 | ₩343.99 Billion | +9.77% |
| 2018-12-31 | ₩313.38 Billion | +7.80% |
| 2017-12-31 | ₩290.71 Billion | +0.51% |
| 2016-12-31 | ₩289.25 Billion | -4.76% |
| 2015-12-31 | ₩303.71 Billion | -1.32% |
| 2014-12-31 | ₩307.77 Billion | +4.59% |
| 2013-12-31 | ₩294.28 Billion | +2.45% |
| 2012-12-31 | ₩287.25 Billion | +3.20% |
| 2011-12-31 | ₩278.34 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Handok's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22773499040000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩227.73 Billion | 79.28% |
| Other Components | ₩59.53 Billion | 20.72% |
| Total Equity | ₩287.26 Billion | 100.00% |
Handok Competitors by Market Cap
The table below lists competitors of Handok ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lavras Gold Corp.
OTCQX:LGCFF
|
$51.81 Million |
|
CoTec Holdings Corp.
V:CTH
|
$51.82 Million |
|
JASTECH Ltd
KQ:090470
|
$51.82 Million |
|
Kronos Bio Inc
NASDAQ:KRON
|
$51.83 Million |
|
Los Andes Copper Ltd
OTCQX:LSANF
|
$51.80 Million |
|
Yangarra Resources Ltd
PINK:YGRAF
|
$51.80 Million |
|
Taokaenoi Food & Marketing Public Company Limited
BK:TKN
|
$51.80 Million |
|
D0X
F:D0X
|
$51.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Handok's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 338,731,977,980 to 287,262,262,410, a change of -51,469,715,570 (-15.2%).
- Net loss of 52,562,762,550 reduced equity.
- Dividend payments of 4,129,059,900 reduced retained earnings.
- Other factors increased equity by 5,222,106,880.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-52.56 Billion | -18.3% |
| Dividends Paid | ₩4.13 Billion | -1.44% |
| Other Changes | ₩5.22 Billion | +1.82% |
| Total Change | ₩- | -15.19% |
Book Value vs Market Value Analysis
This analysis compares Handok's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.52x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩22838.20 | ₩10820.00 | x |
| 2018-12-31 | ₩22572.56 | ₩10820.00 | x |
| 2019-12-31 | ₩24757.03 | ₩10820.00 | x |
| 2020-12-31 | ₩27703.50 | ₩10820.00 | x |
| 2021-12-31 | ₩27899.55 | ₩10820.00 | x |
| 2022-12-31 | ₩27595.57 | ₩10820.00 | x |
| 2023-12-31 | ₩24610.83 | ₩10820.00 | x |
| 2024-12-31 | ₩20871.26 | ₩10820.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Handok utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.36%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 2.75x
- Recent ROE (-18.30%) is below the historical average (0.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 5.95% | 4.97% | 0.82x | 1.47x | ₩-11.26 Billion |
| 2012 | 2.01% | 1.83% | 0.72x | 1.52x | ₩-22.96 Billion |
| 2013 | 4.18% | 3.75% | 0.69x | 1.61x | ₩-17.12 Billion |
| 2014 | 0.48% | 0.42% | 0.68x | 1.67x | ₩-29.30 Billion |
| 2015 | -0.57% | -0.47% | 0.68x | 1.78x | ₩-31.53 Billion |
| 2016 | -2.30% | -1.63% | 0.64x | 2.22x | ₩-34.54 Billion |
| 2017 | 1.71% | 1.16% | 0.65x | 2.25x | ₩-23.56 Billion |
| 2018 | 2.60% | 1.79% | 0.68x | 2.12x | ₩-22.75 Billion |
| 2019 | 10.25% | 7.38% | 0.63x | 2.20x | ₩854.30 Million |
| 2020 | 7.07% | 5.35% | 0.61x | 2.15x | ₩-11.17 Billion |
| 2021 | 0.86% | 0.64% | 0.62x | 2.19x | ₩-35.10 Billion |
| 2022 | 2.81% | 1.96% | 0.62x | 2.29x | ₩-27.30 Billion |
| 2023 | -8.50% | -5.51% | 0.66x | 2.33x | ₩-62.67 Billion |
| 2024 | -18.30% | -10.36% | 0.64x | 2.75x | ₩-81.29 Billion |
Industry Comparison
This section compares Handok's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Handok (002390) | ₩267.88 Billion | 5.95% | 2.00x | $51.81 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |